What is the strongest predictor of progression-free survival and response to gefitinib in non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

In an early IPASS study, EGFR mutation was found to be the strongest predictor of progression-free survival and response to gefitinib. [155]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!